Almirall has secured exclusive rights to commercialize Wynzora for the treatment of plaque psoriasis in Europe from MC2 Therapeutics. The agreement is worth up to €15 million ($18 million) in upfront ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results